Overview

A Study of Temodar With PCI-24781 for Patients With Recurrent Glioma

Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about treatment for a type of brain cancer called glioma. This clinical trial is for people with glioma who have been cancer-free for a period of time but their cancer has come back. The primary goals of this clinical trial are the following: - To determine the recommended dose of PCI-24781 with metronomic temozolomide - To evaluate side effects associated with using PCI-24781 with metronomic temozolomide
Phase:
Phase 1
Details
Lead Sponsor:
University of Nebraska
Collaborator:
Xynomic Pharmaceuticals, Inc.
Treatments:
Abexinostat
Temozolomide